A live webcast of the virtual fireside chat will be available on Isoray’s Investor Relations section of the Company’s website at https://isoray.com/investors/presentations/.

The published article on the study, Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institution, was authored by Joshua L. Rodríguez-López, MD, Ankur K. Patel, MD, Ronald M. Benoit, MD, Sushil Beriwal, MD, Ryan P. Smith, MD, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.